Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProPhase Labs, Inc.PRPH · Entity 8699 | Chief Accounting Officer | May 23, 2022 | May 25, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProPhase Labs, Inc.
Report date May 23, 2022 · Filed May 25, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0005SEC Table I · non-derivative | Direct | 34,872 |
Ending reported balance
After 2022-05-23 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-05-23 · Exercise / conversion · Acquired 25,000 · Balance 32,428 F1: On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. Row 2 · 2022-05-23 · Exercise / conversion · Acquired 14,250 · Balance 46,678 F1: On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. Row 3 · 2022-05-23 · Tax withholding · Disposed 11,806 · Balance 34,872 F1: On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.15 · Expires 2024-09-26 | Direct | 0 |
Reported balance
After 2022-05-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-23 · Exercise / conversion · Disposed 25,000 · Balance 0 F1: On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. F2: 25% of the shares subject to this option were vested and exercisable as of September 26, 2017, the date of grant, and the remaining 75% of the shares vested in three annual installments beginning on September 26, 2018. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.18 · Expires 2025-12-03 | Direct | 35,750 |
Reported balance
After 2022-05-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-23 · Exercise / conversion · Disposed 14,250 · Balance 35,750 F1: On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. F3: These options vest in four equal annual installments beginning December 4, 2019, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of December 4, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes.
F2: 25% of the shares subject to this option were vested and exercisable as of September 26, 2017, the date of grant, and the remaining 75% of the shares vested in three annual installments beginning on September 26, 2018.
F3: These options vest in four equal annual installments beginning December 4, 2019, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of December 4, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2022 Filed May 25, 2022 21:18 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionOption (right to buy) · Derivative | 14,250 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001493152-22-015066 · ownership.xml · derivative · entry 5 Brady Monica L. · CIK 0001718729 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,750 Underlying: Common Stock · 14,250 shares Expires 2025-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. F3 · derivative.exercise_date: These options vest in four equal annual installments beginning December 4, 2019, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of December 4, 2018. Read SEC document |
| May 23, 2022 Filed May 25, 2022 21:18 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001493152-22-015066 · ownership.xml · derivative · entry 4 Brady Monica L. · CIK 0001718729 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2024-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. F2 · derivative.exercise_date: 25% of the shares subject to this option were vested and exercisable as of September 26, 2017, the date of grant, and the remaining 75% of the shares vested in three annual installments beginning on September 26, 2018. Read SEC document |
| May 23, 2022 Filed May 25, 2022 21:18 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Tax withholdingCommon Stock, par value $0.0005 | 11,806 | $8.47 | $99,996.82 |
DisclosureSEC source: 0001493152-22-015066 · ownership.xml · nonDerivative · entry 3 Brady Monica L. · CIK 0001718729 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,872 F1 · kind: On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. Read SEC document |
| May 23, 2022 Filed May 25, 2022 21:18 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionCommon Stock, par value $0.0005 | 14,250 | $3.18 | $45,315.00 |
DisclosureSEC source: 0001493152-22-015066 · ownership.xml · nonDerivative · entry 2 Brady Monica L. · CIK 0001718729 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. Read SEC document |
| May 23, 2022 Filed May 25, 2022 21:18 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | Exercise / conversionCommon Stock, par value $0.0005 | 25,000 | $2.15 | $53,750.00 |
DisclosureSEC source: 0001493152-22-015066 · ownership.xml · nonDerivative · entry 1 Brady Monica L. · CIK 0001718729 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On May 23, 2022, the Reporting Person acquired net 27,444 shares of common stock upon the exercise of stock options to purchase 39,250 shares of common stock, less 11,806 shares of common stock withheld to cover the exercise price and applicable taxes. Read SEC document |
| August 16, 2020 Filed Aug 18, 2020 20:30 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 150,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001493152-20-016204 · ownership.xml · derivative · entry 1 Brady Monica L. · CIK 0001718729 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-08-16 F1 · derivative.exercise_date: The transaction reported in this row involves a grant by the Issuer to the Reporting Person of options to purchase the Issuer's common stock that will vest in four equal annual installments beginning August 16, 2020, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of August 16, 2020. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:05 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001493152-19-018255 · ownership.xml · derivative · entry 1 Brady Monica L. · CIK 0001718729 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-11-19 F1 · derivative.exercise_date: The transaction reported in this row involves a grant by the Issuer to the Reporting Person of options to purchase the Issuer's common stock that will vest in four equal annual installments beginning November 20, 2019, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of November 20, 2019. Read SEC document |
| December 04, 2018 Filed Dec 18, 2018 00:15 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001493152-18-017621 · ownership.xml · derivative · entry 1 Brady Monica L. · CIK 0001718729 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2025-12-03 F1 · derivative.exercise_date: The transaction reported in this row involves a grant by the Issuer to the Reporting Person of options to purchase the Issuer's common stock that will vest in four equal annual installments beginning December 04, 2019, as detailed in a stock option award agreement by and between the Issuer and the Reporting Person, dated as of December 04, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.